RMC-6236 + cetuximab for colorectal or pancreatic cancer (RMC-GI-102_B) - Clinical Trial

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
[RMC-GI-102_B] Study of RMC-6236 in Combination with Cetuximab with or without mFOLFOX6 in Patients with Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma ? Subprotocol B
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00115669
NCT: NCT06445062
Phase
Phase I/II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate